Paper22621925
Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways.
Sears CR and 1 other. J Biol Chem, 2012. Cited by 54 papers, by iCite.
Cite this record
ConductScience Library. Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways. Papers, record 22621925. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22621925
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| DNA Breaks, Double-Stranded | Major topic |
| Cell Line, Tumor | |
| Flow Cytometry | |
| Humans | |
| Microscopy, Fluorescence | |
| Signal Transduction |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA082741 | NCI NIH HHS | United States | R01CA082741 | PubMed and NIH |
| CA082741 | NCI NIH HHS | United States | R01CA082741 | PubMed and NIH |
Source NIH RePORTER
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6196777 | Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II). | Proc Natl Acad Sci U S A | 1983 | https://conductscience.org/library/papers/6196777 | PubMed |
| 2 | 15872216 | Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts. | Nucleic Acids Res | 2005 | https://conductscience.org/library/papers/15872216 | PubMed |
| 3 | 20142431 | Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and DNA ligase 4. | J Exp Med | 2010 | https://conductscience.org/library/papers/20142431 | PubMed |
| 4 | 10329699 | Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA. | J Biol Chem | 1999 | https://conductscience.org/library/papers/10329699 | PubMed |
| 5 | 9826654 | DNA end-joining catalyzed by human cell-free extracts. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9826654 | PubMed |
| 6 | 21376743 | Choosing the right path: does DNA-PK help make the decision? | Mutat Res | 2011 | https://conductscience.org/library/papers/21376743 | PubMed |
| 7 | 20351327 | Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20351327 | PubMed |
| 8 | 3491805 | The effect of combined treatment with platinum complexes and ionizing radiation on DNA in vitro. | Int J Radiat Biol Relat Stud Phys Chem Med | 1986 | https://conductscience.org/library/papers/3491805 | PubMed |
| 9 | 17898768 | Rag mutations reveal robust alternative end joining. | Nature | 2007 | https://conductscience.org/library/papers/17898768 | PubMed |
| 10 | 8662830 | Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. | J Biol Chem | 1996 | https://conductscience.org/library/papers/8662830 | PubMed |
| 11 | 14576837 | Cisplatin: mode of cytotoxic action and molecular basis of resistance. | Oncogene | 2003 | https://conductscience.org/library/papers/14576837 | PubMed |
| 12 | 12829693 | Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA. | J Biol Chem | 2003 | https://conductscience.org/library/papers/12829693 | PubMed |
| 13 | 8544761 | Photochemical production of double-strand breaks in cellular DNA. | Mutagenesis | 1995 | https://conductscience.org/library/papers/8544761 | PubMed |
| 14 | 9338102 | Maintaining genetic stability through TP53 mediated checkpoint control. | Cancer Surv | 1997 | https://conductscience.org/library/papers/9338102 | PubMed |
| 15 | 11095672 | Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK. | Nucleic Acids Res | 2000 | https://conductscience.org/library/papers/11095672 | PubMed |
| 16 | 8648250 | Concomitant low dose-rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. | Int J Radiat Biol | 1996 | https://conductscience.org/library/papers/8648250 | PubMed |
| 17 | 12020431 | Examining the non-homologous repair process following cisplatin and radiation treatments. | Int J Radiat Biol | 2002 | https://conductscience.org/library/papers/12020431 | PubMed |
| 18 | 21296855 | Global cancer statistics. | CA Cancer J Clin | 2011 | https://conductscience.org/library/papers/21296855 | PubMed |
| 19 | 17873173 | Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). | Chest | 2007 | https://conductscience.org/library/papers/17873173 | PubMed |
| 20 | 8519652 | Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. | Br J Cancer | 1995 | https://conductscience.org/library/papers/8519652 | PubMed |
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42619032 | Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/42619032 | PubMed |
| 41854291 | Cell-cycle-specific lesion evolution rather than inhibition of double-strand-break repair underpins cisplatin radiosensitization. | Mol Oncol | 2026 | https://conductscience.org/library/papers/41854291 | PubMed |
| 41201971 | T2R5 Agonist Phendione Decreases Cell Viability and Induces Apoptosis in Head and Neck Squamous Cell Carcinoma. | Mol Cancer Ther | 2026 | https://conductscience.org/library/papers/41201971 | PubMed |
| 40422185 | Effects of Cisplatin on the Radiation Response and DNA Damage Markers in Peripheral Blood Lymphocytes Ex Vivo. | Cells | 2025 | https://conductscience.org/library/papers/40422185 | PubMed |
| 40402512 | Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies. | Blood Cancer Discov | 2025 | https://conductscience.org/library/papers/40402512 | PubMed |
| 39931862 | GCN2 in Cancer: Molecular Mechanisms to Therapeutic Potential. | Curr Cancer Drug Targets | 2026 | https://conductscience.org/library/papers/39931862 | PubMed |
| 38947172 | Chemo-small extracellular vesicles released in cisplatin-resistance ovarian cancer cells are regulated by the lysosomal function. | J Extracell Biol | 2024 | https://conductscience.org/library/papers/38947172 | PubMed |
| 38486992 | Metal nanoparticles for cancer therapy: Precision targeting of DNA damage. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38486992 | PubMed |
| 38010604 | Nutritional Support of Crocin on Neurobehavioral Disabilities Induced by Cisplatin-Based Chemotherapy in Rats. | Neurochem Res | 2024 | https://conductscience.org/library/papers/38010604 | PubMed |
| 36614204 | Spectroscopic Characterization and Biological Activity of Hesperetin Schiff Bases and Their Cu(II) Complexes. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36614204 | PubMed |
| 36450764 | A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance. | Nat Commun | 2022 | https://conductscience.org/library/papers/36450764 | PubMed |
| 36335317 | HMG20A was identified as a key enhancer driver associated with DNA damage repair in oral squamous cell carcinomas. | BMC Oral Health | 2022 | https://conductscience.org/library/papers/36335317 | PubMed |
| 35806243 | Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35806243 | PubMed |
| 35435331 | Identification of a Crosstalk among TGR5, GLIS2, and TP53 Signaling Pathways in the Control of Undifferentiated Germ Cell Homeostasis and Chemoresistance. | Adv Sci (Weinh) | 2022 | https://conductscience.org/library/papers/35435331 | PubMed |
| 35085879 | DNA Repair Capacity for Personalizing Risk and Treatment Response - Assay Development and Optimization in Human Peripheral Blood Mononuclear Cells (PBMCs). | DNA Repair (Amst) | 2022 | https://conductscience.org/library/papers/35085879 | PubMed |
| 35018240 | DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/35018240 | PubMed |
| 34685687 | Cisplatin Reduces the Frequencies of Radiotherapy-Induced Micronuclei in Peripheral Blood Lymphocytes of Patients with Gynaecological Cancer: Possible Implications for the Risk of Second Malignant Neoplasms. | Cells | 2021 | https://conductscience.org/library/papers/34685687 | PubMed |
| 34359683 | Targeting BRF2 in Cancer Using Repurposed Drugs. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34359683 | PubMed |
| 34250022 | The Role of Tumour Metabolism in Cisplatin Resistance. | Front Mol Biosci | 2021 | https://conductscience.org/library/papers/34250022 | PubMed |
| 33512317 | DNA damage-how and why we age? | Elife | 2021 | https://conductscience.org/library/papers/33512317 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22621925
GET https://conductscience.org/api/papers/v1/22621925/references?page=2